Together, our findings reveal ASGR1 as a candidate underlying genetic predisposition for liver injury, calling special attention to the potential risks associated with ASGR1 inhibition as a therapeutic strategy for the prevention and treatment of CAD. Here, ASGR1 is linked to coronary artery disorder.